Is NTEC or DIVO a better dividend investment in 2026?

NTEC currently yields 20.77% with a 5% 5-year dividend growth rate. DIVO yields 6.62% with 5% growth. The better choice depends on your goal: NTEC offers higher current income.

What is the dividend yield difference between NTEC and DIVO?

NTEC has a forward dividend yield of 20.77% ($2.00/share annually). DIVO yields 6.62% ($2.91/share annually). The yield gap is 14.15 percentage points.

Home › Compare › NTEC vs DIVO

NTEC vs DIVO: Dividend Comparison 2026

NTEC yields 20.77% · DIVO yields 6.62%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 NTEC wins by $45.6K in total portfolio value

INVESTMENT

TIME HORIZON10 years

NTEC

● Live price

20.77%

Share price

$9.63

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$76.5K

Annual income

$7,308.86

Full NTEC calculator →

DIVO

● Live price

6.62%

Share price

$44.00

Annual div

$2.91

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$31.0K

Annual income

$1,008.47

Full DIVO calculator →

Portfolio growth — NTEC vs DIVO

📍 NTEC pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	NTEC	DIVO
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, NTEC + DIVO cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

NTEC pays

DIVO pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NTEC

Annual income on $10K today (after 15% tax)

$1,765.32/yr

After 10yr DRIP, annual income (after tax)

$6,212.53/yr

DIVO

Annual income on $10K today (after 15% tax)

$562.67/yr

After 10yr DRIP, annual income (after tax)

$857.20/yr

At 15% tax rate, NTEC beats the other by $5,355.33/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NTEC + DIVO for your $10,000?

NTEC: 50%DIVO: 50%

100% DIVO50/50100% NTEC

Portfolio after 10yr

$53.8K

Annual income

$4,158.67/yr

Blended yield

7.74%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on NTEC right now

NTEC

Analyst Ratings

Buy

Hold

Consensus: Buy

DIVO

No analyst data

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NTEC buys

DIVO buys

No recent congressional trades found for NTEC or DIVO in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricNTECDIVO

Forward yield	20.77% ✓	6.62%
Annual dividend / share	$2.00	$2.91 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$76.5K ✓	$31.0K
Annual income after 10y	$7,308.86 ✓	$1,008.47
Total dividends collected	$44.4K ✓	$8.4K
Payment frequency	quarterly	quarterly
Sector	Stock	ETF

Year-by-year: NTEC vs DIVO ($10,000, DRIP)

Year	NTEC Portfolio	NTEC Income/yr	DIVO Portfolio	DIVO Income/yr	Gap
1← crossover	$12,777	$2,076.84	$11,362	$661.96	+$1.4K → NTEC
2	$16,151	$2,479.95	$12,860	$702.91	+$3.3K → NTEC
3	$20,212	$2,929.82	$14,504	$743.56	+$5.7K → NTEC
4	$25,053	$3,426.51	$16,303	$783.73	+$8.8K → NTEC
5	$30,776	$3,969.42	$18,268	$823.31	+$12.5K → NTEC
6	$37,488	$4,557.19	$20,408	$862.17	+$17.1K → NTEC
7	$45,300	$5,187.86	$22,737	$900.20	+$22.6K → NTEC
8	$54,329	$5,858.83	$25,266	$937.31	+$29.1K → NTEC
9	$64,699	$6,567.01	$28,008	$973.42	+$36.7K → NTEC
10	$76,537	$7,308.86	$30,977	$1,008.47	+$45.6K → NTEC

NTEC vs DIVO: Complete Analysis 2026

NTEC — Stock

Intec Pharma Ltd, a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. The company's lead product candidate is Accordion Pill Carbidopa/Levodopa, which is in a Phase III clinical trial for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients. It is also developing Accordion Pill Zaleplon that is in a Phase III clinical trial as a treatment for the induction and maintenance of sleep in patients suffering from insomnia; a product candidate, which has completed a Phase I clinical trial for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug induced ulcers; and AP-CBD/THC, AP-THC, and AP-CBD product candidates with Cannabidiol and 9-Tetrahydrocannabinol for the treatment of various pain indications. Intec Pharma Ltd. has a research collaboration agreement with Merck to explore using the Accordion Pill platform for development program. The company was formerly known as Intec Pharmaceuticals (2000) Ltd. and changed its name to Intec Pharma Ltd in March 2004. Intec Pharma Ltd was founded in 2000 and is based in Jerusalem, Israel.

Full NTEC Calculator →

DIVO — ETF

DIVO is an ETF of high-quality large cap companies with a history of dividend and earnings growth, along with a tactical covered call* strategy on individual stocks. DIVO is strategically designed to offer high levels of total return on a risk-adjusted basis.

Full DIVO Calculator →

📬

Get this NTEC vs DIVO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NTEC vs SCHD NTEC vs JEPI NTEC vs O NTEC vs KO NTEC vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.